ACADIA to Host Conference Call and Webcast on Monday, November 9,2009, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Nov. 2, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will report its unaudited financial results forthe third quarter ended September 30, 2009 on Monday, November 9, 2009,after the U.S. financial markets close. ACADIA's management will host aconference call and webcast on Monday, November 9, 2009, at 5:00 p.m.Eastern Time to discuss ACADIA’s financial results and developmentprograms.
The conference call may be accessed by dialing 866-510-0707 forparticipants in the U.S. or Canada and 617-597-5376 for internationalcallers (reference passcode 92783090). A telephone replay of theconference call may be accessed through November 23, 2009 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 21130876). The conference callalso will be webcast live on ACADIA’s website, www.acadia-pharm.com,under the investors section and will be archived there until November23, 2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA’s product candidates includepimavanserin in Phase III for Parkinson’s disease psychosis incollaboration with Biovail, a product candidate in Phase II for chronicpain and a product candidate in Phase I for glaucoma, both incollaboration with Allergan, and AM-831 in IND-track development incollaboration with Meiji Seika Kaisha. All of the product candidates inACADIA’s pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, VicePresident and Chief Financial Officer
858-558-2871